Skip to main content
Inpatient Procedure Code

XW0438A

Introduction of Obecabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 10

Introduce Obecab Autoleuc in Central Vein, Perc, New Tech 10

Axis Breakdown

Every ICD-10-PCS code is exactly seven characters, one per axis. Each character's meaning is defined by its position in the code.

PositionValueMeaning
1
SectionX

New Technology

2
Body SystemW

Anatomical Regions

3
Root Operation0

Introduction

Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products

4
Body Part4

Central Vein

5
Approach3

Percutaneous

6
Device / Substance / Technology8

Obecabtagene Autoleucel

7
New Technology GroupA

New Technology Group 10

Potential MS-DRG Relationships (FY2026)

The MS-DRG grouper treats this as a non-operating-room procedure. It appears in the surgical logic of 1 MS-DRG:

  • MDC PRE — Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies: DRG 018

From the CMS MS-DRG Definitions Manual, Appendix E. Actual DRG assignment depends on the complete claim.

Contextual Map

Every relationship of XW0438A in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.

PCS table

  • XW0[PCS table]
  • [object Object] — Section: [object Object] [Section]: “[object Object]”
  • [object Object] — Body System: [object Object] [Body System]: “[object Object]”
  • [object Object] — Operation: [object Object] [Operation]: “[object Object]”

MS-DRG participation

  • DRG 018 — CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL AND OTHER IMMUNOTHERAPIES [MS-DRG]: “CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL AND OTHER IMMUNOTHERAPIES — Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies (MDC PRE)”

MDC crossing · diagnoses (1333)

  • Pre-MDC[MDC crossing]: “Pre-MDC — the grouper's crossing between diagnoses and procedures: a principal diagnosis sets the MDC, and same-MDC procedures move the stay to its surgical DRGs.”
  • A36.0 — Pharyngeal diphtheria [Same-MDC diagnosis]: “Pharyngeal diphtheria — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
  • A36.1 — Nasopharyngeal diphtheria [Same-MDC diagnosis]: “Nasopharyngeal diphtheria — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
  • A36.2 — Laryngeal diphtheria [Same-MDC diagnosis]: “Laryngeal diphtheria — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
  • A54.5 — Gonococcal pharyngitis [Same-MDC diagnosis]: “Gonococcal pharyngitis — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
  • A56.4 — Chlamydial infection of pharynx [Same-MDC diagnosis]: “Chlamydial infection of pharynx — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
  • and 1328 more

Nearest codes

  • XW0338A — Introduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10 [One axis away]
  • XW0433A — Introduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10 [One axis away]
  • XW0434A — Introduction of Cefepime-taniborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10 [One axis away]
  • XW0435A — Introduction of Ceftobiprole Medocaril Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10 [One axis away]
  • XW04387 — Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7 [One axis away]
  • XW04388 — Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8 [One axis away]
  • XW0439A — Introduction of Odronextamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10 [One axis away]
  • XW043BA — Introduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10 [One axis away]

Change history

No changes recorded for this code — unchanged since the FY2026 (April) baseline of the change ledger.